Statistics

Total Visits

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)8

Select a period of time:

Number of views in the range

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)3

Views

Views
November 20230
December 20230
January 20240
February 20240
March 20241
April 20242
May 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States3
 

Top cities views

Views